Scott Armstrong
MD
Chair, Department of Pediatric Oncology
👥Biography 个人简介
Scott Armstrong at Dana-Farber has made landmark contributions to the epigenetic basis of MLL-rearranged leukemia. His discovery that DOT1L (a histone H3K79 methyltransferase) is required for MLL-fusion leukemia maintenance, and his development of the first DOT1L inhibitor (pinometostat) that entered clinical trials, established DOT1L as a first validated epigenetic therapeutic target specifically for MLL-rearranged leukemia — a high-risk leukemia subtype prevalent in infants.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
Representative Works 代表性著作
📄Data Sources 数据来源
Last updated: 2026-02-01 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Drew M. Pardoll
Johns Hopkins University
Padmanee Sharma
MD Anderson Cancer Center
Naiyer A. Rizvi
Columbia University Irving Medical Center
关注 Scott Armstrong 的研究动态
Follow Scott Armstrong's research updates
留下邮箱，当我们发布与 Scott Armstrong（Dana-Farber Cancer Institute）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment